Fibrogenesis in Crohn's disease

被引:223
作者
Burke, John P.
Mulsow, Jurgen J.
O'Keane, Conor
Docherty, Neil G.
Watson, R. William G.
O'Connell, P. Ronan
机构
[1] Mater Misericordiae Univ Hosp, Dept Surg, Dublin 7, Ireland
[2] Mater Misericordiae Univ Hosp, Dept Pathol, Dublin 7, Ireland
[3] Univ Coll Dublin, Conway Inst, Dublin 2, Ireland
[4] Univ Coll Dublin, Sch Med & Med Sci, Dublin 2, Ireland
关键词
D O I
10.1111/j.1572-0241.2006.01010.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
INTRODUCTION: Over one-third of patients with Crohn's disease (CD) will develop an intestinal stricture and the great majority of these will require at least one surgical procedure. While the pathogenesis of inflammation in CD has been extensively investigated, knowledge of stricture pathogenesis remains limited. The aim of this review is to discuss the current understanding of fibrogenesis in CD and to outline potential directions in research and therapeutics. METHODS: The electronic literature (January 1966 to May 2006) on CD-associated fibrosis was reviewed. Further references were obtained by cross-referencing from key articles. RESULTS: CD-associated fibrosis results from chronic transmural inflammation and a complex interplay among intestinal mesenchymal cells, cytokines, and local inflammatory cells. The fibroblast is the key cell type mediating stricture formation. The cytoarchitecure of the bowel wall is altered with disruption of the muscularis mucosa, thickening of the muscularis propria, and deposition of collagen throughout. The cytokine TGF-beta appears critical in this process, acting to increase growth factor and extracellular matrix (ECM) production and dysregulate ECM turnover. Potential therapeutic interventions are likely to concentrate on modulating down-stream targets of TGF-beta. CONCLUSIONS: Greater understanding of the biology of fibrostenosis is likely to yield significant advances in our ability to care for patients with stricturing CD. Potential dividends of this approach include identification of novel therapeutic targets and biomarkers useful for prognostication and therapeutic monitoring.
引用
收藏
页码:439 / 448
页数:10
相关论文
共 124 条
[31]  
Dietz DW, 2001, J AM COLL SURGEONS, V192, P330, DOI 10.1016/S1072-7515(01)00775-X
[32]   Rho-dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins) [J].
Eberlein, M ;
Heusinger-Ribeiro, J ;
Goppelt-Struebe, M .
BRITISH JOURNAL OF PHARMACOLOGY, 2001, 133 (07) :1172-1180
[33]   Innate immunity and mucosal bacterial interactions in the intestine [J].
Eckmann, L .
CURRENT OPINION IN GASTROENTEROLOGY, 2004, 20 (02) :82-88
[34]  
Ehrlich H P, 1988, Prog Clin Biol Res, V266, P243
[35]  
EHRLICH HP, 1981, EXP MOL PATHOL, V34, P1
[36]   POSTOPERATIVE RECURRENCE OF CROHNS-DISEASE IN RELATION TO RADICALITY OF OPERATION AND SULFASALAZINE PROPHYLAXIS - A MULTICENTER TRIAL [J].
EWE, K ;
HERFARTH, C ;
MALCHOW, H ;
JESDINSKY, HJ .
DIGESTION, 1989, 42 (04) :224-232
[37]  
FARMER RG, 1976, GASTROENTEROLOGY, V71, P245
[38]  
Farrokhyar F, 2001, AM J GASTROENTEROL, V96, P501
[39]   LONG-TERM FOLLOW-UP OF STRICTUREPLASTY IN CROHNS-DISEASE [J].
FAZIO, VW ;
TJANDRA, JJ ;
LAVERY, IC ;
CHURCH, JM ;
MILSOM, JW ;
OAKLEY, JR .
DISEASES OF THE COLON & RECTUM, 1993, 36 (04) :355-361
[40]   Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease [J].
Fedorak, RN ;
Gangl, A ;
Elson, CO ;
Rutgeerts, P ;
Schreiber, S ;
Wild, G ;
Hanauer, SB ;
Kilian, A ;
Cohard, M ;
LeBeaut, A ;
Feagan, B .
GASTROENTEROLOGY, 2000, 119 (06) :1473-1482